Last reviewed · How we verify
An Open-label Clinical Trial to Evaluate the Immunity Persistence of Live Attenuated Varicella Vaccine At 6 and 10 Years After Booster Dose Immunization with Live Attenuated Varicella Vaccine
This an open-label phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 6 and 10 years after booster dose.
Details
| Lead sponsor | Sinovac (Dalian) Vaccine Technology Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | ENROLLING_BY_INVITATION |
| Enrolment | 414 |
| Start date | 2024-09-16 |
| Completion | 2031-12 |
Conditions
- Varicella
Interventions
- Live Attenuated Varicella Vaccine
Primary outcomes
- Seropositive rate — at 6 years after booster vaccination
The seropositive rate of varicella-zoster virus (VZV) antibodies at 6 years after booster vaccination - Seropositive rate — at 10 years after booster vaccination
The seropositive rate of VZV antibodies at 10 years after booster vaccination - GMT of VZV antibody — at 6 years after booster vaccination
The GMT of VZV antibodies at 6 years after booster vaccination - GMT of VZV antibody — at 10 years after booster vaccination
The GMT of VZV antibodies at 10 years after booster vaccination
Countries
China